Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery
Marc Lallemant, Billy Amzal, Patumrat Sripan, Saïk Urien, Tim R Cressey, Nicole Ngo-Giang-Huong, Virat Klinbuayaem, Boonsong Rawangban, Prapan Sabsanong, Thitiporn Siriwachirachai, Tapnarong Jarupanich, Prateep Kanjanavikai, Phaiboon Wanasiri, Suporn Koetsawang, Gonzague Jourdain, Sophie Le Coeur, PHPT-5 site investigators, Marc Lallemant, Billy Amzal, Patumrat Sripan, Saïk Urien, Tim R Cressey, Nicole Ngo-Giang-Huong, Virat Klinbuayaem, Boonsong Rawangban, Prapan Sabsanong, Thitiporn Siriwachirachai, Tapnarong Jarupanich, Prateep Kanjanavikai, Phaiboon Wanasiri, Suporn Koetsawang, Gonzague Jourdain, Sophie Le Coeur, PHPT-5 site investigators
Abstract
Introduction: Infants born to women living with HIV initiating combination antiretroviral therapy (cART) late in pregnancy are at high risk of intrapartum infection. Mother/infant perinatal antiretroviral intensification may substantially reduce this risk.
Methods: In this single-arm Bayesian trial, pregnant women with HIV receiving standard of care antiretroviral prophylaxis in Thailand (maternal antenatal lopinavir-based cART; nonbreastfed infants 4 weeks' postnatal zidovudine) were offered "antiretroviral intensification" (labor single-dose nevirapine plus infant zidovudine-lamivudine-nevirapine for 2 weeks followed by zidovudine-lamivudine for 2 weeks) if their antenatal cART was initiated ≤8 weeks before delivery. A negative birth HIV-DNA polymerase chain reaction (PCR) followed by a confirmed positive PCR defined intrapartum transmission. Before study initiation, we modeled intrapartum transmission probabilities using data from 3738 mother/infant pairs enrolled in our previous trials in Thailand using a logistic model, with perinatal maternal/infant antiretroviral regimen and predicted viral load at delivery as main covariates. Using the characteristics of the women enrolled who received intensification, prior intrapartum transmission probabilities (credibility intervals) with/without intensification were estimated. After including the transmission data observed in the current study, the corresponding Bayesian posterior transmission probability was derived.
Results: No intrapartum transmission of HIV was observed among the 88 mother/infant pairs receiving intensification. The estimated intrapartum transmission probability was 2·2% (95% credibility interval 0·5-6·1) without intensification versus 0·3% (0·0-1·6) with intensification. The probability of superiority of intensification over standard of care was 94·4%. Antiretroviral intensification appeared safe.
Conclusion: Mother/infant antiretroviral intensification was effective in preventing intrapartum transmission of HIV in pregnant women receiving ≤8 weeks antepartum cART.
Conflict of interest statement
The authors have no funding or conflicts of interest to disclose.
Figures
Source: PubMed